InternationalUSRemember you can easily switch between MIP US and MIP International at any time

LVMH outlines anti-counterfeiting battle


Nikolay Livadkin, anti-counterfeiting manager at Louis Vuitton, told delegates at the Pharmaceutical Trademarks Group conference in Cannes last Thursday that cracking down on sales of fakes over the internet had become one of the great challenges his company faced

Nikolay Livadkin, anti-counterfeiting manager at Louis Vuitton, told delegates at the Pharmaceutical Trademarks Group (PTMG) conference in Cannes last Thursday that cracking down on sales of fakes over the internet had become one of the great challenges his company faced.

"It's a question of survival for us to protect our brand on the internet. The stakes are high," Livadkin said.

Louis Vuitton's IP department...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Hot mic allowing audience to hear backstage conversation before @uspto's Michelle Lee's talk @CSIS on patent reform. Nothing juicy though!

Jul 6 2015 04:59 ·  reply ·  retweet ·  favourite
ManagingIP profile

Weekly blog roundup by @mdloney feat. @TheCIPA BOB, SCOTUS, Taylor Swift, S101 & Eli Lilly http://t.co/ogkQlc4Px1 http://t.co/tx3F7GnHz3

Jul 6 2015 11:42 ·  reply ·  retweet ·  favourite
ManagingIP profile

In summary: DON'T PANIC! https://t.co/HwaRrt6Mz1

Jul 6 2015 11:12 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements